Hot Topics


Governments can ration access to cancer drugs, or break patent monopolies. Why is rationing so popular?:

Duke letter to White House on the problems with the TPP IP Chapter

Attached below is a May 20, 2015 letter from Duke researchers to the White House Office of Science and Technology Policy, setting our problems in the TPP IP Chapter. The letter is signed by Jason Cross, the Director of the Innovation & Technology Policy Lab (ITPLab) at the Sanford School of Public Policy & Duke Law School, at Duke University.

The whole letter (available in PDF format here) is worth reading. Here are a few sections from the letter:

Two page summary: What does the TPP do as regards prices of drugs and other medical technologies?

Attached is a 2 page summary of the main provisions in the Trans-Pacific Partnership Agreement (TPP) that will lead to higher prices for drugs and other medical technologies.

A pdf version of the note is available here:

What does the TPP do as regards prices of drugs and other medical technologies?

KEI TPP Briefing note 2015:2
June 10, 2015

WTO TRIPS Council (June 2015): LDC Group Presentation on the Extension of the Decision for Pharmaceutical Products

The LDC Group delivered the following statement on Wednesday, 8 June 2015 during WTO TRIPS Council discussions on their request on the extension of the decision on pharmaceutical products.


Mr. Chairman,

I make this presentation on behalf of the LDCs group. We thank you for calling this meeting and for your report.

WTO TRIPS Council: World Health Organization issues unequivocal support of LDC transition period for pharmaceutical products

Today, on Wednesday, 10 June 2015, the World Trade Organization's TRIPS Council discussed the LDC Group's Request for an Extension of the Transitional Period Under Article 66.1 of the TRIPS Agreement for Least Developed Country Members with Respect to Pharmaceutical Products and for Waivers from the Obligation of Articles 70.8 and 70.9 of the TRIPS Agreement (Source: IP/C/W/605).

Sign-on Letter to USTR, be honest about impact of TPP on prices, access to medicines

KEI is circulating a sign on letter to be sent to Ambassador Michael Froman of USTR. We learned that in a USTR has been stating that there was no evidence that stronger intellectual property rules created barriers for access to medicine.

This is a shocking statement for USTR to make, and we are seeking confirmation and clarification of USTR's assertion. The text of our letter follows below.

If you would like to sign on to this letter, please send your name, city and state of residence, and affiliation if any, along with contact details (only for confirmation if necessary), to:

Article in Medium, on the TPP

I have written an article for Medium, titled: TPP, designed to make medicine more expensive, reforms more difficult. (Link here)

New leaks from RECP negotiations on IP, India and ASEAN proposals

Last week, KEI published the October 3, 2014 Korea proposals for the RCEP IP Chapter (, and earlier we published a Japan proposal for the RCEP IP Chapter (

Today we are publishing two new proposals for the RCEP IP Chapter, the proposals by

US Copyright office proposes limits on damages, injunctions, for Orphan Works, contradicting TPP language

The US Copyright Office has proposed limitations on damages and injunctions, when "orphan" copyrighted works are infringed.

Leaked IP Chapter, Regional Comprehensive Economic Partnership (RCEP) FTA, Oct 3, 2014

Attached (here) is the October 3, 2014 version of the Draft Text, of the Intellectual Property Chapter, for the Regional Comprehensive Economic Partnership (RCEP), Free Trade Agreement, tabled by South Korea in the negotiations. (More about the RCEP here)

The next round of negotiation will be held in Kyoto, Japan from 8-12 June.

WTO TRIPS Council (February 2015): EU statement on LDC extension of transition period for pharmaceutical products

The following statement was delivered by the European Union at the February 2015 session in response to the proposal by the LDC Group Request for an Extension of the Transitional Period Under Article 66.1 of the TRIPS Agreement for Least Developed Country Members with Respect to Pharmaceutical Products and for Waivers from the Obligation of Articles 70.8 and 70.9 of the TRIPS Agreement.

In particular, the European Union noted,

June 2015: WTO reports on India's Section 3(d) and compulsory licensing provisions - WTO Trade Policy Review - India

On 2 June 2015 and 4 June 2015, the World Trade Organization (WTO) is conducting a trade policy review of India. All members of the WTO are subject to review under the Trade Policy Review Mechanism (TPRM). The TPRM takes place in the "Trade Policy Review Body which is actually the WTO General Council — comprising the WTO’s full membership — operating under special rules and procedures" (Source: WTO, Trade Policy Reviews: Brief Introduction).

Bucharest: KEI Europe Hosts Side Event on Access to Affordable HCV Medicines Saturday 30 May 10:00

For any of you in Bucharest this weekend at the EASL conference on liver disease, KEI Europe will host a side event on access to affordable HCV medicines on Saturday morning.

Pathways to Widespread Access: Affordable HCV Medicines in Romania
Date: 10:00-12:00 Saturday, 30 May 2015
Venue: Novotel Bucharest City Centre, Conference Room Lyon (Mezzanine Floor)

A Panel Discussion:

Peter Beyer, World Health Organization (WHO). Access to Medicines and Intellectual Property Rights

WHA68 KEI side event: Andrew Goldman speaking on compulsory licensing of HCV drug patents

On Thursday, May 21, 2015, KEI and KEI Europe hosted a side event at the 68th World Health Assembly on compulsory licensing of patents on drugs, vaccines, and diagnostic tests. The event was graciously hosted by UNAIDS in the Kofi Annan room.

Put the patents at risk, not the patients

The TPP, following a plethora of other trade agreements involving the United States, the European Union and Japan as trading partners, seeks to expand and extend drug monopolies, by requiring lower standards for the grant of patents, extensions of patent terms, exclusive rights in test data, among other measures. These proposals and polices are designed to have the predictable effect of making drug prices higher.

WHA68: Statement of HAI/KEI on Follow-up to 2014 HLM on comprehensive review + assessment of prevention and control of NCDs

On Tuesday, 26 May 2015, the following statement was delivered in Committee B of the 68th World Health Assembly on behalf of Stichting Health Action International and Knowledge Ecology International on the topic: Follow-up to the 2014 high-level meeting of the United Nations General Assembly to undertake a comprehensive review and assessment of the progress achieved in the prevention and control of noncommunicable diseases.

Syndicate content